Vitamin B12: A key player in cellular reprogramming and tissue regeneration

The research was focused on an experimental process known as cellular reprogramming which is thought to mimic the early phases of tissue repair. The IRB team found that cellular reprogramming in mice consumes large amounts of vitamin B12. Indeed, the depletion of vitamin B12 becomes a limiting factor that delays and impairs some aspects of the reprogramming process. Considering the abundance of vitamin B12 in the normal diet of mice, the investigators were surprised to observe that the simple supplementation of vitamin B12 significantly enhanced the efficiency of reprogramming.

Therapeutic potential in ulcerative colitis

The researchers validated their findings in a model of ulcerative colitis, demonstrating that the intestinal cells initiating repair undergo a process similar to cellular reprogramming and also benefit from vitamin B12 supplementation. Patients with intestinal bowel disease could potentially benefit from vitamin B12 supplementation.

"Our research uncovers a critical role of vitamin B12 in cellular reprogramming and tissue repair. These findings hold promise for regenerative medicine, with the potential to benefit patients through an improved nutrition," says Dr. Manuel Serrano.

Understanding the role of vitamin B12 in cellular reprogramming

In this study, the researchers delved into the metabolic requirements of cellular reprogramming and found that vitamin B12 is a limiting factor for a particular branch of metabolism involved in a reaction known as methylation. Precisely, the DNA of the cells initiating reprogramming or tissue repair require very high levels of this methylation reaction and therefore of vitamin B12. The researchers discovered that vitamin B12 insufficiency during reprogramming or tissue repair resulted in significant epigenetic changes, leading to errors in the function of multiple genes.

"Supplementation with vitamin B12 corrected this imbalance, resulting in enhanced gene function fidelity and overall improved reprogramming efficiency," confirms Dr. Marta Kovatcheva, first author of the study and a postdoctoral researcher in the same laboratory. Dr. Kovatcheva will open a new laboratory in 2024 at the Istituto Fondazione di Oncologia Molecolare ETS (IFOM) in Milan, Italy, which will be focused on the study of partially reprogrammed cells in vivo.

Separate study links vitamin B12 to lower inflammation

The group led by Dr. Serrano has recently published another study, in collaboration with the laboratory of Dr. Rosa Lamuela-Raventós at the University of Barcelona (UB), and Dr. Ramon Estruch at the Hospital Clínic of Barcelona, in which they concluded that people with higher levels of vitamin B12 in blood had lower levels of inflammatory markers (IL-6 and CRP). The researchers also observed a similar relationship in aged mice. These observations suggest that vitamin B12 exerts anti-inflammatory action by reducing these markers in the body and they provide valuable insights into the potential health benefits of vitamin B12.

This research project was conducted in collaboration with the groups of Dr. Guido Kroemer at the Institut Gustave Roussy (in France), the laboratory led by Dr. Oscar Yanes at the Universitat Rovira i Virgili (Spain), IRB Barcelona's Bioinformatics and Biostatistics Core Facility, led by Dr. Camille Stephan-Otto Attolini and the Histopathology Core Facility, led by Dr. Neus prats both at IRB Barcelona and the University of Barcelona.

Dr. Manuel Serrano is presently working at Altos Labs, Cambridge, UK.

The project has received funding from the following agencies: the Barcelona Institute of Science and Technology (BIST); the Asociación Española Contra el Cáncer (AECC); the European Molecular Biology Organization (EMBO); the Karolinska Institute, the Swedish Research Council; the Ligue contre le Cancer; the Agence National de la Recherche (ANR); the Association pour la recherche sur le cancer (ARC); the Fondation pour la Recherche Médicale (FRM); the European Joint Programme on Rare Diseases (EJPRD); the European Research Council (ERC); the Institut National du Cancer (INCa); the Institut Universitaire de France; the Mark Foundation; the Seerave Foundation; "la Caixa" Foundation; the Milky Way Research Foundation; the Spanish Ministry of Science, the European Regional Development Fund (ERDF); and the Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixment of Catalonia.